Investor Presentaiton
ZIRCON Phase III trial of TLX250-CDx for imaging of cc RCC
Study overview
ZIRCON
Eligible Patients
Single indeterminate renal mass ≤7cm
Surgical removal
diameter on CT or MRI suspicious for ccRCC
Scheduled for surgical removal as part of
management plan
TLX250-CDx
PET/CT scan
and histology as
standard of truth
TELIX
PHARMACEUTICALS
For personal use only
International, multi-centre, Phase III trial in ~252 patients with an indeterminate renal mass suspicious of CCRCC
Primary endpoint: Sensitivity and specificity of PET/CT imaging with TLX250-CDx to non-invasively detect ccRCC
in patients with indeterminate renal masses, using histology as standard of truth (after surgical removal)
35 sites participating
•
> 85% recruited, progressing well towards completion
United States, Canada, Europe, Turkey, Australia
ZIRDAC-JP Phase I/II bridging trial of TLX250-CDx in Japan
Phase I objectives met, Phase II in planning, potential to include Chinese patients to expand Asian utility
Telix Pharmaceuticals Limited (ASX: TLX)
42View entire presentation